Jim Cramer Highlights Eli Lilly’s Drug Potential Beyond Diabetes and Obesity

Group 1 - Eli Lilly and Company is recognized for its GLP-1 diabetes and weight loss drug, which has potential applications in treating hypertension, dementia, and alcoholism [1] - The company plans to invest $6.5 billion to enhance its pipeline production across various therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and gastrointestinal conditions [2] Group 2 - While Eli Lilly shows potential as an investment, certain AI stocks are considered to have greater upside potential and less downside risk [3]